{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:47Z","timestamp":1792417427843,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background and Aim:<\/jats:title>\n                    <jats:p>Golimumab is a fully human tumor necrosis factor-alpha inhibitor that is highly effective in the management of ankylosing spondylitis (AS). A major limitation of golimumab is nonresponse, resulting from low drug concentrations, which is primarily due to antidrug antibodies (ADAs). The aim of this study was to assess the trough concentration of golimumab and the prevalence of ADA formation in patients with AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An enzyme-linked immunosorbent assay was used to quantify golimumab trough concentrations and ADAs in 59 Iraqi patients with AS; AS disease activity was also evaluated using the Ankylosing Spondylitis Disease Activity Score (ASDAS). Regression analysis was performed to determine predictors of disease activity and ADA formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean age of the participants was 37.86 years, most of them (52 patients) were men, and the median number of golimumab doses administered was 7. The median ASDAS score was 3.1, and approximately 35% of patients had low disease activity (ASDAS score &lt;2.1). The range of golimumab trough concentration was 0.21\u20131.38 mg\/L with a median of 0.41 mg\/L, and ADAs were detected in 8 patients (13.6%). Trough concentrations were higher in ADA-negative patients and were significantly negatively correlated with ASDAS scores. Regression analysis identified the trough drug concentration as the only predictor of both disease activity and ADA formation, with lower concentrations responsible for higher disease activity and a higher chance of developing ADAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Drug concentration is an important determinant of disease activity, and routine monitoring of trough concentration is recommended for therapeutic drug monitoring of golimumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001527","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:05:42Z","timestamp":1792415142000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Drug Monitoring of Golimumab to Predict Disease Activity and Antidrug Antibodies Status in Patients with Ankylosing Spondylitis"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1248-4797","authenticated-orcid":false,"given":"Sadeel A.","family":"Shanshal","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Mosul, Nineveh, Iraq;"},{"name":"Department of Pharmacology, College of Medicine, University of Mosul, Nineveh, Iraq; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamil H.","family":"Othman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, University of Mosul, Nineveh, Iraq; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Younis","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, University of Mosul, Nineveh, Iraq."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"R1-20261019","doi-asserted-by":"crossref","first-page":"vi4","DOI":"10.1093\/rheumatology\/key001","article-title":"Progress in our understanding of the pathogenesis of ankylosing spondylitis","volume":"57","author":"Simone","year":"2018","journal-title":"Rheumatology"},{"key":"R2-20261019","doi-asserted-by":"crossref","first-page":"297","DOI":"10.25259\/SNI_294_2022","article-title":"A brief human history of ankylosing spondylitis: a scoping review of pathogenesis, diagnosis, and treatment","volume":"13","author":"Murphy","year":"2022","journal-title":"Surg Neurol Int."},{"key":"R3-20261019","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13075-020-02226-8","article-title":"TNF-\u03b1 inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis","volume":"22","author":"Yang","year":"2020","journal-title":"Arthritis Res Ther."},{"key":"R4-20261019","first-page":"e61500","article-title":"The use of TNF-\u03b1 inhibitors in active ankylosing spondylitis treatment","volume":"16","author":"Zouris","year":"2024","journal-title":"Cureus"},{"key":"R5-20261019","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/PPA.S403437","article-title":"Influence of disease acceptance on the quality of life of patients with ankylosing spondylitis \u2013 single centre study","volume":"17","author":"Wysocki","year":"2023","journal-title":"Patient Prefer Adherence."},{"key":"R6-20261019","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1080\/21645515.2020.1836919","article-title":"Golimumab (anti-TNF monoclonal antibody): where we stand today","volume":"17","author":"Melo","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"R7-20261019","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2147\/DDDT.S107587","article-title":"Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials","volume":"10","author":"Toussirot","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"R8-20261019","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"R9-20261019","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J Rheumatol."},{"key":"R10-20261019","doi-asserted-by":"crossref","first-page":"e021082","DOI":"10.1136\/bmjopen-2017-021082","article-title":"Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany","volume":"8","author":"Kr\u00fcger","year":"2018","journal-title":"BMJ Open"},{"key":"R11-20261019","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double\u2010blind, placebo\u2010controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"R12-20261019","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study","volume":"74","author":"Deodhar","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"R13-20261019","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front Immunol."},{"key":"R14-20261019","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","article-title":"Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis","volume":"29","author":"Thomas","year":"2015","journal-title":"BioDrugs"},{"key":"R15-20261019","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R16-20261019","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1136\/annrheumdis-2015-207978","article-title":"Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"R17-20261019","first-page":"110","article-title":"Optimal concentration range of golimumab in patients with axial spondyloarthritis","volume":"36","author":"Mart\u00ednez-Feito","year":"2018","journal-title":"Clin Exp Rheumatol."},{"key":"R18-20261019","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/03009742.2021.1875040","article-title":"Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study","volume":"50","author":"Gehin","year":"2021","journal-title":"Scand J Rheumatol."},{"key":"R19-20261019","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bcp.13192","article-title":"Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?","volume":"83","author":"Bastida","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R20-20261019","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5114\/reum\/185429","article-title":"Comparison of ankylosing spondylitis disease activity score and bath ankylosing spondylitis disease activity index tools in assessment of axial spondyloarthritis activity","volume":"62","author":"Wi\u0105k-Walerowicz","year":"2024","journal-title":"Reumatologia"},{"key":"R21-20261019","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis","volume":"27","author":"Linden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"R22-20261019","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"R24-20261019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"R25-20261019","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fimmu.2015.00152","article-title":"Immunogenicity of anti-TNF-\u03b1 biotherapies: I. Individualized medicine based on immunopharmacological evidence","volume":"6","author":"Bendtzen","year":"2015","journal-title":"Front Immunol."},{"key":"R26-20261019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000524593","article-title":"Therapeutic drug monitoring of golimumab for the prediction of long-term clinical remission in patients with ulcerative colitis","volume":"103","author":"Tawa","year":"2022","journal-title":"Digestion"},{"key":"R27-20261019","first-page":"570","article-title":"Golimumab, the newest TNF-\u03b1 blocker, comes of age","volume":"33","author":"Papagoras","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"R28-20261019","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5414\/CPP48596","article-title":"Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity","volume":"48","author":"Xu","year":"2010","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R29-20261019","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/ard.2011.154799","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"R30-20261019","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/key309","article-title":"Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"58","author":"Leu","year":"2019","journal-title":"Rheumatology"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:05:46Z","timestamp":1792415146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001527","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"2026-06-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}